BUSINESS

Sumitomo Dainippon Sues 15 More Companies over Latuda Patent

February 27, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sumitomo Dainippon Pharma said on February 24 that it has filed a patent infringement lawsuit in the US against 15 more companies over the use patent of its flagship antipsychotic Latuda (lurasidone) after the Osaka-based company sued two generic makers…

To read the full story

Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018

BUSINESS

Fuji, Richter Strike Co-Development Pact in Women’s Health
March 25, 2026
ASKA Inks AI Target Discovery Pact with Insilico in Women’s Health
March 25, 2026
Shionogi to Fully Acquire Sleep Disorder JV SASS
March 25, 2026
Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
Kyorin Bags Global Rights to UBE’s Early-Stage Asset
March 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste

By Ken Yoshino

Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…